Evidence map›Paper›PMID 29970184›Full record

Trial reportBMC pharmacology & toxicology2018

Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.

Girish Parthan, Shobhit Bhansali, Anura V Kurpad, Rama Walia, Kishor Bhat, Anil Bhansali

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC pharmacology & toxicology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02097342 (A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02097342 phase4unknown statusnot on this map

A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy

TypeinterventionalSponsorPost Graduate Institute of Medical Education and Research, ChandigarhRan2013 to 2015Enrolled30ConditionsType 2 Diabetes Mellitus, Insulin Sensitivity/ResistanceArmsLinagliptin, Placebo, Voglibose
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Girish ParthanDepartment of Endocrinology, Post Graduate Institute of Medical Education and Research, Sector- 12, Chandigarh, PIN Code-160012, India.
Shobhit BhansaliDepartment of Endocrinology, Post Graduate Institute of Medical Education and Research, Sector- 12, Chandigarh, PIN Code-160012, India.
Anura V KurpadDepartment of Physiology, St. John's Medical College, Bangalore, India.
Rama WaliaDepartment of Endocrinology, Post Graduate Institute of Medical Education and Research, Sector- 12, Chandigarh, PIN Code-160012, India.
Kishor BhatDepartment of Physiology, St. John's Medical College, Bangalore, India.
Anil BhansaliDepartment of Endocrinology, Post Graduate Institute of Medical Education and Research, Sector- 12, Chandigarh, PIN Code-160012, India. anilbhansaliendocrine@gmail.com.
Post Graduate Institute of Medical Education and Research · INSt.John's Medical College Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDipeptidyl peptidase 4 (DPP4) inhibitors improve glycemic control by promoting GLP1-mediated glucose-dependent insulin secretion and suppression of glucagon. Sitagliptin and vildagliptin have been shown to improve insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). However, these patients had uncontrolled blood glucose at inclusion; therefore, the improvement in insulin sensitivity observed in these studies could be attributed to the drug per se and/or reduction in glucotoxicity. This study examines the effect of linagliptin on insulin sensitivity and β-cell function in patients with well-controlled T2DM.

methodsThirty patients with T2DM of duration ≤5 years, and having HbA1c < 7.5% were randomized to receive linagliptin, voglibose or placebo (n = 10 each), and were followed up for 6 months. Insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamp, and insulin secretory response was measured by basal (M

resultsThe median HbA1c of the study subjects at inclusion was 6.9% and there was no significant difference among the groups in terms of age, duration of diabetes, body mass index (BMI), HbA1c, insulin sensitivity, AUC of C-peptide and M

conclusionLinagliptin modestly improves glycemic profile in patients with well controlled T2DM; however, it may not have an effect on insulin sensitivity in these patients.

trial registrationRetrospectively Registered in Clinicaltrials.gov (ID number, NCT02097342 ). Registered: March 27, 2014.

Indexed as

AdultBlood GlucoseDiabetes Mellitus, Type 2Double-Blind MethodFemaleGlycated HemoglobinHumansHypoglycemic AgentsInositolInsulin ResistanceInsulin-Secreting CellsLinagliptinMaleMiddle AgedPostprandial PeriodBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInositolLinagliptinvogliboseT2DM, β-cell function, insulin sensitivity, linagliptin, voglibose

Identifiers

PMID29970184
PMCPMC6030784
OpenAlexW2810670609

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.